Ratings for Vertex Pharmaceuticals VRTX were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 9 | 5 | 0 | 1 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 1 |
| 2M Ago | 1 | 3 | 1 | 0 | 0 |
| 3M Ago | 1 | 3 | 4 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $389.53, a high estimate of $440.00, and a low estimate of $347.00. This upward trend is apparent, with the current average reflecting a 5.02% increase from the previous average price target of $370.91.
Interpreting Analyst Ratings: A Closer Look
The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Olivia Brayer | Cantor Fitzgerald | Raises | Overweight | $440.00 | $415.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Sell | $379.00 | $332.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $415.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $415.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $379.00 | $347.00 |
| Gena Wang | Barclays | Raises | Overweight | $415.00 | $408.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $397.00 | $390.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Paul Matteis | Stifel | Maintains | Hold | $373.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $364.00 | $359.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $347.00 | $350.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $415.00 | $389.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Overweight | $380.00 | $370.00 |
| Paul Matteis | Stifel | Raises | Hold | $373.00 | $340.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $390.00 | $380.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vertex Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Vertex Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Vertex Pharmaceuticals analyst ratings.
Discovering Vertex Pharmaceuticals: A Closer Look
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Vertex Pharmaceuticals: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Vertex Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 6.39% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 41.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.47%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.92%, the company showcases effective utilization of assets.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
